



DIAGNOCURE INC.

PRESS RELEASE
For immediate release

Ticker Symbol: CUR

DIAGNOCURE ANNOUNCES 2005 FIRST QUARTER RESULTS

QUEBEC CITY (March 4, 2005) – DiagnoCure Inc. (TSX: CUR), a leading developer and provider of innovative high-value immunoassay and molecular diagnostics for early detection of cancer, today announced its financial results for the first quarter ended January 31, 2005.

During the quarter, DiagnoCure completed a pilot study on bronchial aspirations from 73 patients of which 32 were normal samples and 41 confirmed lung cancer cases. The results demonstrated that the combined sensitivity of the molecular markers was 90 % compared with a corresponding cytologic sensitivity of only 37 %. Combined sensitivity of the molecular markers and cytology was 98 %. The Company intends to develop a first generation molecular assay and undertake a multicenter clinical trial in 2005 to validate these promising preliminary results. The Company also continues to explore additional diagnostic applications of the molecular markers for lung cancer detection utilizing sputum, expectorate and blood samples.

Gen-Probe Inc., DiagnoCure's PCA3 worldwide exclusive licensee, has successfully transferred the PCA3 technology to its APTIMA format. They are now completing their product development effort and finalizing the scale-up for manufacturing of the Gen-Probe ASR (*Analyte Specific Reagent*) assay. Gen-Probe confirmed its intention to launch the PCA3 ASR version before the end of 2005.

DiagnoCure also announced an exclusive worldwide license with McGill University for its CDP/Cux protein technology for the detection of breast and other cancers. The Company intends, through its developmental expertise in nucleic acid amplification and antibody-based technology platforms, to develop different diagnostic approaches to breast and other cancer detection.

Financial Results

Total revenues for the first quarter of 2005 were \$1,783,252 compared with \$1,171,721 for the first quarter of 2004. Products sales were \$533,159 for the first quarter of 2005 compared to \$208,091 for the same period a year ago.

Operating expenses and cost of sales rose from \$1,569,821 for the first quarter of 2004 to \$2,390,859 for the same period in 2005, an increase of \$821,038. This is primarily due to the increase in the general overall activity of the Company and, more specifically, to the disclosure of the stock-based compensation expenses, initiated in 2005 to comply with new accounting regulations, which increased by \$255,930. For the first quarter of 2005, DiagnoCure recorded a net loss of \$607,607, or \$0.02 per share, compared with a net loss of \$398,100 or \$0.01 per share, for the first quarter of 2004.

At the end of the first quarter, cash, short-term and long-term investments stood at \$26,873,315 compared to \$6,909,402 at the end of the first quarter of 2004. Management is satisfied that it has adequate cash resources to execute its business plan in the near-term.

FINANCIAL DATA**Consolidated Statements of Operations**

For the periods of	Three months ended January 31	
	2005	2004
Revenues (including interests)	1,783,252	1,171,721
Operating expenses and cost of sales	2,390,859	1,569,821
Gross R&D costs	753,622	565,525
Net loss	(607,607)	(398,100)
Loss per share	(0.02)	(0.01)
Weighted average number of common shares outstanding	34,190,451	29,079,585

Consolidated Balance Sheets

	As at	
	January 31, 2005	October 31, 2004
Cash, cash equivalents, temporary and long-term investments	26,873,315	26,770,466
Total assets	29,612,507	28,925,269
Shareholders' equity	26,616,158	26,879,904

About DiagnoCure

DiagnoCure specializes in the development, production and commercialization of diagnostic tests for the early detection of cancers. DiagnoCure's first product, ImmunoCyt™ /uCyt+™, is an important tool for the diagnosis and monitoring of bladder cancer. In 2003, the Company completed the development of uPM3™, a non-invasive test for the early detection of prostate cancer. In November 2003, DiagnoCure granted an exclusive worldwide license for the use of the PCA3 technology in prostate cancer diagnosis to Gen-Probe (NASDAQ: GPRO). In March 2004, the company launched Odyssey™, an automated microscopy workstation that screens, performs image analysis, reports and archives data and images. After successfully completing a lung cancer pilot study, DiagnoCure is developing a first generation molecular assay and will undertake a multi-center clinical trial in 2005. The Company is continuing the validation of markers for integration into a prototype test for the early detection of kidney cancer. DiagnoCure is headquartered in Quebec City, Canada. Additional information can be found at www.diagnocure.com.

Forward-looking statements

Certain statements in this release are forward-looking. These statements are based on DiagnoCure's current expectations and involve many risks and uncertainties. DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

CONTACT:**DiagnoCure Inc.**

Pierre Désy

President and Chief Executive Officer

(418) 527-6100

e mail: communications@diagnocure.com